A. Prechtl

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

F. Jänicke, A. Prechtl, Christoph Thomssen et al. · JNCI Journal of the National Cancer Institute · 2001 · 438 citations · Full text

Medicine, Oncology, Breast Oncology +13

Qualitative and Quantitative Assessment of Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or Gynecologic Malignancies

Silke Steinbach, Thomas Hummel, Christina Böhner et al. · Journal of Clinical Oncology · 2009 · 238 citations · Full text

Medicine, Oncology, Pharmacology +17

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

F. Jänicke, L. Pache, Manfred Schmitt et al. · PubMed · 1994 · 120 citations

Medicine, Biochemistry, Oncology +14